ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Up 114.7% in December

ProPhase Labs, Inc. (NASDAQ:PRPH) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 300,239 shares, an increase of 114.7% from the November 30th total of 139,873 shares. Based on an average trading volume of 5,452,214 shares, the short-interest ratio is currently 0.1 days. Approximately 7.2% of the company’s stock are sold short. Approximately 7.2% of the company’s stock are sold short. Based on an average trading volume of 5,452,214 shares, the short-interest ratio is currently 0.1 days.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Wall Street Zen upgraded shares of ProPhase Labs to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of ProPhase Labs in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

ProPhase Labs Price Performance

Shares of NASDAQ:PRPH opened at $0.52 on Monday. ProPhase Labs has a fifty-two week low of $0.50 and a fifty-two week high of $9.35. The business has a 50-day simple moving average of $0.28 and a two-hundred day simple moving average of $0.36. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.14 and a current ratio of 0.14. The firm has a market cap of $2.40 million, a price-to-earnings ratio of -1.33 and a beta of -0.65.

ProPhase Labs (NASDAQ:PRPH) last announced its quarterly earnings results on Wednesday, November 19th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). ProPhase Labs had a negative net margin of 825.01% and a negative return on equity of 482.05%. The company had revenue of $0.88 million for the quarter, compared to analysts’ expectations of $5.69 million. On average, analysts expect that ProPhase Labs will post -1.27 earnings per share for the current year.

Institutional Investors Weigh In On ProPhase Labs

A number of hedge funds have recently added to or reduced their stakes in PRPH. XTX Topco Ltd bought a new position in shares of ProPhase Labs during the 2nd quarter valued at $40,000. Apollon Wealth Management LLC purchased a new stake in ProPhase Labs during the third quarter valued at $84,000. Josh Arnold Investment Consultant LLC bought a new position in ProPhase Labs in the first quarter valued at about $100,000. Accretive Wealth Partners LLC bought a new stake in shares of ProPhase Labs during the 3rd quarter valued at about $114,000. Finally, Susquehanna International Group LLP grew its stake in shares of ProPhase Labs by 290.1% during the 3rd quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock valued at $182,000 after purchasing an additional 295,899 shares during the period. 9.45% of the stock is currently owned by hedge funds and other institutional investors.

About ProPhase Labs

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.